Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase Ib/II Trial of Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-…

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

Washington University School of MedicineNCT06374459